Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
ZYUS Life Sciences ( (TSE:ZYUS) ) has provided an update.
ZYUS Life Sciences has amended its facility subleases, extending their term to January 31, 2030, and converting certain trade payables owed to its landlord into an interest-bearing promissory note of approximately C$4.41 million at 8% annually, with interest-only payments starting in May 2026 and full repayment due by February 1, 2030. The company will also revise its previously announced listed issuer financing exemption offering document to reflect these developments, signaling an effort to restructure obligations, secure long-term operational stability at its premises, and align its capital-raising plans with the updated financial arrangements.
The most recent analyst rating on (TSE:ZYUS) stock is a Buy with a C$1.50 price target. To see the full list of analyst forecasts on ZYUS Life Sciences stock, see the TSE:ZYUS Stock Forecast page.
More about ZYUS Life Sciences
ZYUS Life Sciences Corporation (TSXV: ZYUS) is a clinical-stage life sciences company developing and commercializing novel, non-opioid, cannabinoid-based pharmaceutical drug candidates for pain management. The company focuses on rigorous scientific and clinical research to build an intellectual property portfolio and obtain regulatory approvals for its therapies, targeting improved patient outcomes and enhanced shareholder value.
Average Trading Volume: 6,833
Technical Sentiment Signal: Strong Sell
Current Market Cap: C$52.05M
See more insights into ZYUS stock on TipRanks’ Stock Analysis page.